Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 12Gastrointestinal 6Gynecologic 3Dermatologic 3Breast 3Thoracic 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1CNS 1

Conditions

Ovarian Neoplasms 16Peritoneal Neoplasms 14Colorectal Neoplasms 11Uterine Cervical Neoplasms 9Stomach Neoplasms 9Endometrial Neoplasms 8Neoplasm Metastasis 7Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Mesothelioma 3HIV Infections 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Acquired Immunodeficiency Syndrome 3Uterine Neoplasms 2Uterine Cervical Dysplasia 2Squamous Intraepithelial Lesions 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 41Nivolumab 18atezolizumab 8Specimen Handling 7Docetaxel 7durvalumab 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Ipilimumab 6Cyclophosphamide 6Carboplatin 6fludarabine 4avelumab 4Oxaliplatin 4Leucovorin 4Early Intervention, Educational 4Counseling 4Biopsy 4temsirolimus 3spartalizumab 3pazopanib 3olaparib 3lenvatinib 3cabozantinib 3aldesleukin 3Trastuzumab 3Taxes 3Sirolimus 3Psychiatric Rehabilitation 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Fluorouracil × Gynecologic × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡